Background: Cardiopulmonary bypass (CPB) during cardiac surgery impairs microcirculatory perfusion and is paralleled by vascular leakage. The endothelial angiopoietin/Tie2 system controls microvascular leakage. This study investigated whether targeting Tie2 with the angiopoietin-1 mimetic vasculotide reduces vascular leakage and preserves microcirculatory perfusion in a rat CPB model. Methods: Rats were subjected to 75 min of CPB after treatment with vasculotide or phosphate buffered solution as control or underwent a sham procedure. Microcirculatory perfusion and leakage were assessed with intravital microscopy (n¼10 per group) and Evans blue dye extravasation (n¼13 per group), respectively. Angiopoietin-1, -2, and Tie2 protein and gene expression were determined in plasma, kidney, and lung. Results: CPB immediately impaired microcirculatory perfusion [5 (4e8) vs 10 (7e12) vessels per recording, P¼0.002] in untreated CPB rats compared with sham, which persisted after weaning from CPB. CPB increased circulating angiopoeietin-1, -2, and soluble Tie2 concentrations and reduced Tie2 messenger ribonucleic acid (mRNA) expression in
Impaired microcirculatory perfusion caused by cardiopulmonary bypass (CPB) delays recovery after cardiac surgery as a result of fluid overload. We investigated the effect of the angiopoietin-1 mimetic vasculotide on microcirculatory perfusion after CPB in rats. Vasculotide decreased vascular leakage in lung and preserved microcirculatory perfusion after CPB without affecting the endogenous angiopoietin system. These animal data suggest that vasculotide should be further investigated as a possible therapeutic option in patients undergoing cardiac surgery with CPB.
Microcirculatory perfusion is impaired during cardiac surgery with cardiopulmonary bypass (CPB) and remains disturbed in the early postoperative period. 1, 2 Microcirculatory perfusion disturbances are associated with postoperative organ dysfunction and delayed postoperative recovery. 3e5 These complications are thought to be the result of oedema formation with fluid overload as an important predictor of postoperative morbidity, 6 however, effective preventive treatment strategies are unavailable. We recently showed that CPB is associated with endothelial hyperpermeability 7 and is paralleled by vascular leakage and expression of pulmonary and renal injury markers. 8 A therapeutic strategy aimed at reducing vascular leakage during CPB might therefore improve microcirculatory perfusion and limit postoperative organ dysfunction after CPB. The endothelial angiopoietin/Tie2 system is involved in endothelial barrier regulation and vascular leakage. Tie2 is a vascular enriched tyrosine kinase receptor that is controlled by angiopoietin binding. 9 In quiescence, angiopoietin-1 binding phosphorylates Tie2 and promotes endothelial integrity while suppressing inflammation. During stress, as observed in CPB, stored angiopoietin-2 is released from endothelial Weibel-Palade bodies and antagonistically induces barrier disruptive signalling. 7, 9 Recent studies confirmed these increased concentrations of circulating angiopoietin-2 after CPB, suggestive of alterations in angiopoietin/Tie2 signalling. 4, 10, 11 Moreover, increased circulating concentrations of angiopoietin-2 are predictive for prolonged hospital stay and mortality in patients undergoing CPB, 12 suggesting an important regulatory role of this system in CPB-induced endothelial hyperpermeability and postoperative organ dysfunction.
Vasculotide, an angiopoietin-1 mimetic, is a recently introduced drug that functions by promoting Tie2 phosphorylation and subsequently restores or promotes endothelial stability as shown by reduced vascular leakage in animal models of sepsis, 13 acute kidney 14 or lung injury, 15 and haemorrhagic shock. 16 Although patient studies also suggested a possible important role of the angiopoietin/Tie2 system in CPB patients, this has not been confirmed using a therapeutic strategy. 4,7,9e12 We therefore aimed to investigate the relationship between Tie2 regulation and microcirculatory perfusion in a rat CPB model. We hypothesised that vascular leakage is an important contributor to microcirculatory perfusion disturbances during CPB and is paralleled by alterations in the endothelial angiopoietin/Tie2 system. Modulating the angiopoietin/Tie2 system with vasculotide might prevent vascular leakage and preserve microcirculatory perfusion during CPB.
Methods

Animals
All procedures were approved by the Institutional Animal Care and Use Committee of the VU University, The Netherlands (Animal welfare number: ANES 12-03; ANES 12-03A02), conducted in accordance with EU Directive (2010/63EU) and reported in accordance with the Animal Research: Reporting of In Vivo Experiments guidelines. 18 Surgeries were performed under isoflurane, fentanyl, and local lidocaine anaesthesia and analgesia. Male Wistar rats weighing 375e425 g (Charles River Laboratories, Brussels, Belgium) were housed in a temperature-controlled room (12/12 h light dark cycle, 20e23 C, 40e60% humidity) with food and water ad libitum. Rats were randomly assigned to undergo CPB with vasculotide treatment (CPBþVT, n¼9) or phosphate buffered solution (PBS) treatment as control (CPB, n¼10) or underwent sham procedure (sham, n¼10) for microcirculatory perfusion measurements and molecular analyses (Fig. 1A) . For vascular leakage measurements, another n¼12 rats per group were included (Fig. 1B ). Rats were culled by blood withdrawal under isoflurane 5.0% inhalation 60 min after weaning from CPB. Kidneys and lungs were isolated and stored in À80 C for molecular analysis. Vasculotide (Vasomune Therapeutics, Vancouver, BC, Canada) was dissolved in PBS and 200 ng was administered via the jugular vein cannula 20 min before CPB. Optimal treatment concentration was based on dose-response experiments and previously performed rat studies by our group. 16 Equal volumes of PBS were administered in control rats. was administered as additional analgesia and repeated approximately every 30e40 min during the experimental procedure. Arterial blood gas and haematocrit measurements were performed at baseline and repeated at 10, 30, and 60 min of extracorporeal circulation and 10 and 60 min after weaning from CPB, or at corresponding time points for sham experiments. The left cremaster muscle was isolated under warm saline superfusion, spread out on a heated platform (34 C), and covered with gas impermeable plastic film (Saran wrap) as previously described. 2, 8, 16 Heparin (500 IU kg À1 , LEOPharma, Amsterdam, The Netherlands) was administered followed by cannulation of the right femoral artery with a 20G catheter (Arterial Cannula, Becton Dickinson) for arterial inflow of the CPB circuit. The right jugular vein was catheterised with a 20G catheter (Venflon Pro, Becton Dickinson) for administration of vasculotide or PBS as control. All catheter insertions were preceded by local application of lidocaine 1%.
Anaesthesia and surgical preparation
Arterial BP, ECG, and heart rate were continuously recorded using PowerLab software (PowerLab 8/35, Chart 8.0; ADInstruments Pty, Ltd., Castle Hill, Australia). Before initiation of the study protocol, an additional dose of heparin (500 IU kg À1 )
was given in combination with rocuronium bromide (1.5 mg kg
À1
, Organon, Oss, The Netherlands). During the experiment, rocuronium bromide was given if rats were spontaneously breathing and phenylephrine (0.1 mg) was given when MAP was lower than 45 mm Hg.
Cardiopulmonary bypass
The protocol for CPB was performed as previously described. 2, 8 In summary, the CPB circuit consisted of an open venous reservoir, a roller pump (Pericor SF70, Verder, Haan, Germany), and an oxygenator-heat exchanger with a three-layer hollow fibre membrane for gas exchange (Ing. M. Humbs, Valley, Germany).
19 A 1.0-mm-diameter arterial line (LectroCath, Vygon, Ecouen, France) was connected to the femoral inflow catheter. The circuit was primed with hydroxyethyl starch 6%, 10 ml (HES; Voluven, Fresenius Krabi, Halden, Norway). The right jugular vein catheter was replaced by a modified multiorifice 4.5 French catheter (Desilets-Hoffman, Cook, Bloomington, IN, USA) that was introduced into the right atrium, and CPB was initiated. Flow rates of 150e200 ml kg À1 min
À1
were maintained during extracorporeal circulation, corresponding with 100% of the normal rat cardiac output. 20 The venous cannula was positioned to minimise residual blood flow through the heart, which was associated with minimal residual arterial pulsations. After onset of CPB, ventilation was discontinued and a mixture of oxygen and carbon dioxide was led through the oxygenator membrane of the extracorporeal circuit to maintain pO 2 values between 20.0 and 33.3 kPa and pCO 2 concentrations between 4.6 and 6.0 kPa. Isoflurane (0.8e1.5%) was added to the gas mixture. Temperature was maintained between 35.0 and 35.5 C. At 65 min of CPB, ventilation was restarted at a frequency of 30 min À1 and rats were rewarmed to 36.5 C. Weaning from CPB occurred after 75 min of extracorporeal circulation. The venous cannula was removed and the jugular vein was clamped. Some 15 min after weaning from CPB, protamine hydrochloride (2 mg kg À1 ) was administered to neutralise heparin. The sham procedure was identical to the CPB group except for initiation and weaning of CPB, but including heparin, rocuronium bromide, and protamine administration. No other interventions were made throughout the procedure, and all analyses occurred in an identical manner.
Microcirculatory perfusion measurements and analyses
After stabilisation of the exposed cremaster muscle for at least 30 min, microcirculatory perfusion measurements were performed using a 10Â objective on an intravital microscope (AxiotechVario 100HD, Zeiss, Oberkochen, Germany) connected to a digital camera (scA640, Basler, Ahrensburg, Germany) with a final magnification of 640Â as described previously. 2, 8, 16 Briefly, three regions of the microvasculature in the cremaster muscle with adequate perfusion quality were selected during baseline. These exact predefined regions were followed throughout the experiment. Measurements were performed directly after surgical preparation (baseline), 10 min after initiation of CPB (10 0 CPB), 60 min after start of CPB (60 0 CPB), 10 min after weaning of CPB (10 0 post-CPB), and 60 min after weaning of CPB (60 0 post-CPB) (see also Fig. 1A ). Microcirculatory perfusion analyses were performed offline by an investigator who was blinded to treatment allocation. To objectify microcirculatory perfusion, each video screen was divided into three parts by two vertical lines. 2, 8, 16 The total number of capillaries per screen was obtained by averaging the counted capillary crossings per part of the screen. These small vessels were categorised as continuously perfused (continuous blood flow), intermittently perfused (blood flow was arrested at least once or flow was reversed), or non-perfused capillaries (no flow). The proportion of continuously perfused vessels was calculated by the ratio of the absolute number of continuously perfused capillaries (averaged for each time point) and the total number of capillaries. Similar calculations were performed for intermittently perfused and non-perfused vessels. Pearson coefficients of the intra-and inter-observer correlation of the number of perfused vessels were 0.982 (P<0.0001) and 0.959 (P<0.0001), respectively.
Vascular leakage assessment
All surgical and experimental procedures were performed as described above without isolation of the cremaster muscle. Vascular leakage was seen in the Miles assay based on extravasation of albumin bound Evans blue dye (EBD) as described previously. 21e23 After weaning from CPB, 1 ml of EBD (10 mg dye ml À1 NaCl 0.9%) was administered. One hour after weaning from CPB, rats were culled and the circulation was rinsed with 5Â 20 ml NaCl 0.9% injected in the caudal artery and removed via the jugular vein. Resection samples of the kidney were weighed, placed in di-methyl-formamide (SigmaAldrich Corporation, St. Louis, MO, USA) and incubated in a water bath at 55 C for 48 h. After di-methyl-formamide removal, kidneys were dried at 90 C for 24 h. Extracted EBD and haemoglobin were quantified by spectrophotometry at a wavelength of 610 nm (excitation) and 740 nm (emission) and the EBD/dry organ weight ratio was calculated.
Plasma analyses
Arterial blood was obtained and put into ethylenediaminetetraacetic acid tubes at three different time points: baseline, 75 min after initiation of CPB, and 1 h after weaning of CPB. Blood was centrifuged twice to obtain platelet free plasma and stored at À80 C. Concentrations of angiopoietin-1, -2, and soluble Tie2 were measured using enzyme immunoassay (Cloud-Clone Corporation, Wuhan, Hubei, China) in accordance with the manufacturer's instructions.
Ribonucleic acid analyses
Total ribonucleic acid (RNA) was extracted from 10e30 mg frozen kidney and lung tissue and isolated using the RNeasy mini kit (Qiagen, Venlo, The Netherlands) as previously described. 8, 16 RNA concentration and purity were determined using NanoDrop 1000 (NanoDrop Technologies, Wilmington, DE, USA). A total of 1 mg RNA was transcribed into complementary DNA using an iScript™ cDNA synthesis kit (Bio-Rad, Veenendaal, The Netherlands) using oligo-dT priming. Messenger RNA (mRNA) abundance was measured using a CFX96 Touch™ real-time PCR detection system (Bio-Rad). The following primers were used for quantitative PCR: angiopoietin-1, -2, Tie2, ICAM-1, E-selectin, and P-selectin (Applied Biosystems, Foster City, CA, USA). All mRNA expression levels were normalised to housekeeping gene b2m, calculated by DDcT values and expressed relative to sham rats.
Protein analyses
Frozen kidney and lung tissue was homogenised to obtain protein fractions for western blot analysis as previously described. 23 Expression of signalling proteins were analysed using the following primary antibodies: angiopoietin-1 and -2 (ab183701 and ab155106, monoclonal rabbit, Abcam, Cambridge, MA, USA 
Statistical analysis
All data are expressed as median with inter-quartile and full range and analysed using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA). Sample size was calculated based on previous rat experiments in which CPB induced a decrease in perfused capillaries from 9.2 to 5.5 (1.5) perfused vessels per recording and an increase in vascular leakage from 14 to 26 (8) mg g
À1
. 2 Using an alpha of 0.05 and a power of 0.9, a sample size of eight per group was required for perfusion measurements and a sample size of 10 was required for vascular leakage measurements. Normality of distribution was tested with the Shapiro-Wilk test. Time-dependent differences were analysed with two-way analysis of variance (ANOVA) with repeated measures and Bonferroni post hoc analysis. Two-sided ManneWhitney U-and Wilcoxon tests were used to evaluate differences in-between groups and within groups, respectively. All P values <0.05 were considered as statistically significant.
Results
Haemodynamics and blood gas analysis CPB did not affect heart rate (P¼0.50), but resulted in a decrease in MAP compared with sham [60 (51e77) vs 80 (73e100) mm Hg, P¼0.04; Fig. 2A Fig. 2D ). Comparable pH, base excess, and bicarbonate concentrations were found between sham and untreated CPB rats (Fig. 2E, F, and I ).
Vasculotide did not affect MAP or haematocrit concentrations during CPB (P¼0.50 and P¼0.14, respectively; Fig. 2A and  C) . However, heart rate was reduced during CPB and BP was reduced after weaning from CPB in the vasculotide treated rats Haemodynamic parameters and arterial blood gas analyses. (A) MAP, (B) heart rate, (C) haematocrit concentrations, (D) temperature, (E) pH, (F) base excess, (G) carbon dioxide tension, (H) oxygen tension, and (I) bicarbonate concentrations in rats during and after cardiopulmonary bypass (CPB; blue boxes; n¼10) with vasculotide treatment (CPBþVT; green boxes; n¼9) and sham rats (Sham; white boxes; n¼10). The grey background indicates the period during CPB. Box and whisker plots show median, inter-quartile, and full range, n¼9e10. 
Microcirculatory perfusion
There were no differences in baseline values for microcirculatory perfusion between groups. Onset of CPB immediately impaired microcirculatory perfusion of the cremaster muscle as reflected by a two-fold reduction in the number of perfused capillaries [5 (4e8) vs 10 (7e12) vessels per recording, P¼0.002, Fig. 3A] and five-fold increase in the number of non-perfused vessels [5 (3e6) vs 1 (0e2) vessels per recording, P<0.0001; Fig. 3B Pre-treatment with vasculotide completely preserved microcirculatory perfusion during and after CPB compared with untreated CPB rats as the number of perfused and nonperfused vessels remained stable throughout the experiment (ANOVA RM, P<0.0001; Fig. 3A 
Angiopoietin-1 and -2 protein expression
In kidneys, angiopoietin-2 protein expression was significantly decreased 60 min after weaning from CPB compared with sham rats (P¼0.03; Fig. 5A and D) , whereas angiopoietin-1 protein expression was not affected (P¼0.07; Fig. 5A and C) . In lungs, angiopoietin-1 and -2 protein expression were not affected by CPB compared with sham controls (Fig. 5B , E, and F). Treatment with vasculotide did not affect angiopoietin-1 or -2 protein expression in kidneys and lungs compared with untreated CPB rats ( Fig. 5AeF ; for raw data see Supplementary  Fig. S1 ).
Inflammatory endothelial activation and angiopoietin/ Tie2 gene expression CPB significantly increased ICAM-1, E-selectin, and P-selectin mRNA expression in lungs and kidneys compared with sham group (Fig. 6A and B) . Treatment with vasculotide did not affect endothelial adhesion molecule expression after CPB ( Fig. 6A and B) . In kidneys, no differences were found in angiopoietin-1 and -2 gene expression, but Tie2 gene expression was significantly reduced in rats 60 min after weaning from CPB compared with sham rats (P¼0.004; Fig. 6A ). In lungs, a significant reduction was found in angiopoietin-1, -2, and Tie2 gene expression compared with sham rats (P<0.05; Fig. 6B ). Treatment with vasculotide did not affect gene expression of angiopoietin-1, -2, or Tie2 in kidneys and lungs compared with untreated CPB rats (Fig. 6A and B) .
Discussion
This study shows that CPB in rats is associated with vascular leakage and microcirculatory perfusion disturbances. These disturbances are paralleled by alterations in circulating angiopoietin and soluble Tie2 concentrations, and decreased Tie2 gene expression concentrations in kidney and lung tissue. Treatment with the angiopoietin-1 mimetic vasculotide reduced vascular leakage in lung tissue and preserved microcirculatory perfusion during and after CPB. Therefore, targeting the endothelial angiopoietin/Tie2 system could be a promising intervention to preserve microcirculatory perfusion during CPB.
Our findings are in line with previous patient and animal studies reporting immediate microcirculatory perfusion disturbances after CPB which persist into the early post-CPB period. 1, 8, 24 Several CPB-related factors have previously been investigated in relation to microcirculatory perfusion and outcome, but have failed so far to provide clear molecular targets for preventative therapeutic interventions. We previously showed that mimicking physiological circulatory patterns by using pulsatile flow during CPB appeared to accelerate microvascular restoration, but did not completely preserve microcirculatory perfusion. 25 Furthermore, randomised clinical trials focussing on attenuating the systemic inflammatory response after CPB have not shown clear beneficial effects on patient outcome. 26e28 Moreover, we previously found that these microcirculatory perfusion disturbances were only partly explained by CPB-induced haemodilution and were not restored by correcting systemic haemodynamics.
2,25
The microvascular endothelium seems a central player in microcirculatory perfusion disturbances as it responds to the CPB-associated change in circulatory flow, contact activation, haemodilution, and systemic inflammatory response, and regulates microvascular integrity. Microvascular endothelial hyperpermeability and subsequent vascular leakage may therefore impair microcirculatory perfusion during CPB. Our group recently showed improvement of microcirculatory perfusion after CPB by protecting the endothelial barrier with imatinib treatment. 8 However, imatinib is registered for the treatment of chronic myeloid leukaemia and has a wide range of side-effects, hampering its possible implementation in a cardio-surgical setting.
There is growing interest in the role of the endothelial angiopoietin/Tie2 system as regulator of vascular permeability and its prognostic value in the critically ill. 29 Increased angiopoietin-2 concentrations are currently used as a diagnostic and prognostic marker in sepsis and are predictive for prolonged hospital stay and mortality in patients undergoing CPB. 11,30e32 Moreover, increased circulating angiopoietin-2 is associated with pulmonary vascular leakage in septic patients. 33 In line with these results, we found increased concentrations of plasma angiopoietin-2 during CPB. This was paralleled by increased circulatory concentrations of soluble Tie2, suggestive of endothelial shedding of this receptor during CPB. 34 Counterintuitively, we also found increased concentrations of circulating angiopoetin-1. One could speculate this to be a compensatory reaction after systemic inflammation as observed during CPB, as shedding of Tie2 is thought to inhibit angiopoietin-1/Tie2 binding. 34 Moreover, we found a decrease in Tie2 mRNA expression during CPB. In conditions with acute vascular leakage, there appears to be a decrease in Tie2 receptor expression via multiple mechanisms, such as decreased Tie2 mRNA expression. 35 As a consequence, there is a decrease in availability of Tie2 on the endothelial surface, attenuating its endothelial protective effect and resulting in vascular leakage, which could also be the case in our study. Vasculotide was specifically produced for introduction in a clinical setting after screening of more than 1 billion peptides with large Tie2 binding affinity. 36, 37 Vasculotide binds to Tie2 on a different binding domain than the angiopoietins and activates phosphorylation by clustering Tie2 receptors, without competing with angiopoietin binding. 17, 36 Pretreatment with vasculotide activates downstream endothelial barrier protective pathways, before inflammatory-induced shedding of the extracellular part of the receptor. Therefore, treatment with vasculotide is thought to cause a vessel-stabilising effect which protects the microvasculature when exposed to inflammatory conditions. 15 This mechanism of action is strongly supported by two independent research groups that found that the beneficial effect of vasculotide was severely blunted in mice genetically heterozygous for Tie2 compared with wild type mice. 15, 37 In addition, in vitro dose-dependent phosphorylation of Tie2 by vasculotide was confirmed in renal and pulmonary endothelial cells. 14e17 Since its introduction, vasculotide has shown striking results in reducing vascular leakage in several experimental inflammatory models 13e16 and has shown increased survival during pneumonia in mice. 17 In accordance, we found that vasculotide reduced vascular leakage and preserved cremaster perfusion. Based on these findings, vasculotide appears promising in preserving microcirculatory perfusion, suggesting a possible clinical application to maintain adequate tissue perfusion during CPB. Moreover, we propose that vasculotide could be administered prophylactically in the cardio-surgical setting in contrast to previous studies focussing mainly on the administration of vasculotide after exposure to pro-inflammatory conditions. 13e17
Vasculotide-dependent preservation of microcirculatory perfusion is probably because of reduced vascular leakage. We found that vasculotide reduced vascular leakage in lungs, but not in kidneys. This difference in tissue response to vasculotide could be explained by higher expression of Tie2 in pulmonary endothelial vasculature. 37, 38 We speculate that pulmonary vascular leakage manifests in an earlier stage and it could be that renal vascular dysfunction is more severely present in the 60 min period after weaning from CPB. Future studies focussing on the effect of vasculotide on renal function after CPB are therefore warranted. However, vasculotide has previously been shown to protect renal endothelial barrier function in experimental acute kidney injury, and therefore appears promising in the prevention or treatment of renal dysfunction in critically ill patients. 14 Counterintuitively, lower BPs were found after weaning from CPB in the vasculotide treated rats compared with untreated CPB rats. This effect could not be attributed to the administration of vasculotide, as haemodynamic alterations or changes in blood gas values were not seen in anaesthetised sham rats after vasculotide administration in our previous studies. 16 Although speculative, observed differences could have been the result of minor differences in vasopressor use and fluid administration during CPB between treated and untreated rats. Our study also has limitations. First, we did not perform open chest surgery and did not induce cardioplegic arrest in our experimental CPB model. However, we thereby reduced surgical trauma, enabling observation of the exact effect of extracorporeal circulation on microcirculatory perfusion. Cardiac filling was minimalised by manipulating the jugular vein cannula alongside the right atrium until the arterial pulse pressure diminished. Moreover, observed changes in haemodynamics indicate comparable changes to human setting reflected in CPB associated endothelial activation, haemodilution, decreased BP suggestive of decreased systemic vascular resistance, and decreased bicarbonate concentrations suggestive of oxidative stress. Secondly, although cremaster microcirculatory perfusion measurements are commonly used in experimental models, 2, 12 it would be more desirable to directly measure kidney perfusion and correlate those findings with renal vascular leakage and renal function, which will be the focus of future studies. However, cremaster perfusion measurements are widely accepted and feasible to detect microcirculatory changes without affecting abdominal integrity.
In conclusion, in this study we showed that CPB induced microcirculatory perfusion disturbances in rats, which were paralleled by renal and pulmonary vascular leakage and alterations in the endothelial angiopoietin/Tie2 system. Targeting the endothelial angiopoietin/Tie2 system by the angiopoietin-1 mimetic vasculotide reduced vascular leakage in lungs and preserved microcirculatory perfusion during and after CPB. These results suggest that therapeutic targeting the endothelial angiopoietin/Tie2 system could be promising in preventing microcirculatory disturbances in patients undergoing cardiac surgery with CPB. 
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